"Anti-HIV Agents" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Agents used to treat AIDS and/or stop the spread of the HIV infection. These do not include drugs used to treat symptoms or opportunistic infections associated with AIDS.
| Descriptor ID |
D019380
|
| MeSH Number(s) |
D27.505.954.122.388.077.088
|
| Concept/Terms |
Anti-HIV Agents- Anti-HIV Agents
- Agents, Anti-HIV
- Anti HIV Agents
- Anti-AIDS Agents
- Agents, Anti-AIDS
- Anti AIDS Agents
- Anti-HIV Drugs
- Anti HIV Drugs
- Drugs, Anti-HIV
- AIDS Drugs
- Drugs, AIDS
- Anti-AIDS Drugs
- Anti AIDS Drugs
- Drugs, Anti-AIDS
|
Below are MeSH descriptors whose meaning is more general than "Anti-HIV Agents".
Below are MeSH descriptors whose meaning is more specific than "Anti-HIV Agents".
This graph shows the total number of publications written about "Anti-HIV Agents" by people in this website by year, and whether "Anti-HIV Agents" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1997 | 1 | 0 | 1 |
| 2000 | 2 | 1 | 3 |
| 2001 | 1 | 0 | 1 |
| 2002 | 7 | 3 | 10 |
| 2003 | 5 | 1 | 6 |
| 2004 | 8 | 3 | 11 |
| 2005 | 6 | 2 | 8 |
| 2006 | 2 | 3 | 5 |
| 2007 | 6 | 3 | 9 |
| 2008 | 5 | 5 | 10 |
| 2009 | 13 | 2 | 15 |
| 2010 | 7 | 2 | 9 |
| 2011 | 13 | 4 | 17 |
| 2012 | 8 | 2 | 10 |
| 2013 | 5 | 2 | 7 |
| 2014 | 6 | 5 | 11 |
| 2015 | 6 | 2 | 8 |
| 2016 | 21 | 8 | 29 |
| 2017 | 249 | 96 | 345 |
| 2018 | 206 | 77 | 283 |
| 2019 | 83 | 26 | 109 |
| 2020 | 15 | 18 | 33 |
| 2021 | 10 | 7 | 17 |
To return to the timeline, click here.
Below are the most recent publications written about "Anti-HIV Agents" by people in Profiles.
-
Safety of Tenofovir Disoproxil Fumarate for Pregnant Women Facing the Coronavirus Disease 2019 Pandemic. Am J Epidemiol. 2021 11 02; 190(11):2339-2349.
-
A High Percentage of People With Human Immunodeficiency Virus (HIV) on Antiretroviral Therapy Experience Detectable Low-Level Plasma HIV-1 RNA Following Coronavirus Disease 2019 (COVID-19). Clin Infect Dis. 2021 11 02; 73(9):e2845-e2846.
-
COVID-19-Related Stressors, Sex Behaviors, and HIV Status Neutral Care Among Black Men Who Have Sex With Men and Transgender Women in Chicago, USA. J Acquir Immune Defic Syndr. 2021 11 01; 88(3):261-271.
-
Long-term olfactory dysfunction following coronavirus disease 2019 infection, routine neck dissection at salvage laryngectomy, parotid incidentalomas, and prescribing intranasal steroids in HIV infection. J Laryngol Otol. 2021 Sep; 135(9):753-754.
-
Ethical issues in establishing the efficacy and safety of long-acting injectable pre-exposure prophylaxis for HIV prevention: the HPTN 083 trial. Lancet HIV. 2021 11; 8(11):e723-e728.
-
Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in people living with HIV-1. Clin Microbiol Infect. 2021 Dec; 27(12):1851-1855.
-
Highlights from the 11th IAS Conference on Science. Lancet HIV. 2021 08; 8(8):e459.
-
Drug-induced liver injury associated with lopinavir-ritonavir in patients with COVID-19: a disproportionality analysis of U.S. food and drug administration adverse event reporting system (FAERS) data. Int J Clin Pharm. 2021 Aug; 43(4):1116-1122.
-
COVID-19 in hospitalized HIV-positive and HIV-negative patients: A matched study. HIV Med. 2021 10; 22(9):867-876.
-
SARS-CoV-2 percent positivity and risk factors among people with HIV at an urban academic medical center. PLoS One. 2021; 16(7):e0254994.